只有孕激素的避孕药和血栓形成:一个更新的系统性审查
Naomi K Tepper1, Antoinette T Nguyen1, Maura K Whiteman1
1Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Contraception
|June 1, 2025
概括
仅使用孕激素的避孕药 (POC),特别是储存的甲 (DMPA),可能会增加静脉血栓塞栓症 (VTE) 风险在患有某些疾病的妇女中. 其他POC似乎不会增加静脉瘤或动脉血栓栓塞 (ATE) 风险.
科学领域:
- 生殖健康 生殖健康
- 血栓形成研究研究
- 药物监督 药物监督 药物监督
背景情况:
- 关于仅孕激素避孕药 (POC) 与血栓形成风险之间的关联的证据有限.
- 为了调查这种关联,进行了更新的系统审查.
研究的目的:
- 系统地审查和更新有关风险的证据 静脉血栓栓塞 (VTE) 和动脉血栓塞 (ATE) 与仅使用孕激素的避孕药 (POC) 相关的风险.
- 为了比较POC使用者与非使用者的血栓形成风险,考虑患有血栓性疾病的女性和一般人群.
主要方法:
- 搜索了2016年2月至2022年11月发表的研究,包括2016年1月之前的先前审查中的文章.
- 包括检查POC使用的VTE (深静脉血栓,肺栓塞) 和ATE (心肌梗塞,中风) 风险的研究.
- 评估了所有结果的研究质量和证据确定性.
主要成果:
- 包含了33篇文章;大多数都是不错或质量差的.
- 德波特美德基酸 (DMPA) 的使用与某些血栓性疾病的妇女和一般人群的VTE风险增加有关,但ATE风险没有增加.
- 其他POC,包括levonorgestrel IUD,植入物和仅含孕激素的药丸,没有显示VTE或ATE的风险增加.
结论:
- 使用DMPA可能会增加患有血栓性疾病的女性和一般人群的静脉瘤风险.
- 在使用其他POC时,没有发现VTE或ATE的风险增加.
- 由于有限的数据,需要进一步研究POC使用的安全性,特别是DMPA,在患有血栓性疾病的女性中.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
656
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Birth Control Methods
3.1K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
3.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


